Global T-Cell Therapy Market Report to 2035: Players Include Autolus, Bluebird Bio, Bristol Myers Squibb, Carsgen Therapeutics and Cellectis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global T-Cell Therapy Market – Distribution by Type of Therapy, Target Indications, Target Antigens, Key Players and Key Geographies: Industry Trends and Global Forecasts, 2022-2035” report has been added to ResearchAndMarkets.com’s offering.

This report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. The report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the biopharmaceutical industry.

Company Profiles

• Adaptimmune Therapeutics
• Alaunos Therapeutics
• Autolus
• Bluebird Bio
• Bristol Myers Squibb
• Carsgen Therapeutics
• Cellectis
• Cellular Biomedicine Group
• Gilead Sciences
• GlaxoSmithKline
• Immatics
• Immunocore
• Innovative Cellular Therapeutics
• Iovance Biotherapeutics
• Kuur Therapeutics
• Lion TCR
• Noile-Immune Biotech
• Novartis
• Shanghai GeneChem
• Sinobioway Cell Therapy
• Takara Bio
• Wellington Zhaotai Therapies
• Zelluna immunotherapy

Cancer is known to be one of the leading causes of deaths worldwide. In fact, as per the WHO, close to 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities and national health systems.

Although there are several treatment options available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is difficult to achieve. In this context, immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise.

Amidst the current initiatives undertaken to develop more targeted anti-cancer therapies, T-cell therapies (specifically CAR-T therapies, TCR therapies and TIL therapies) have emerged as a promising option, owing to their ability to eradicate tumor cells from the body with minimal treatment-related side effects.

Overall, this highly specific and promising form of T-cell therapy treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry.

A number of chimeric antigen receptor T-cell (CAR-T) therapies have so far been evaluated and approved for several hematological malignancies, including KYMRIAH (Novartis), YESCARTA (Gilead Sciences), TECARTUST (Gilead Sciences), Breyanzi (Bristol Myers Squibb), AbecmaT (Bristol Myers Squibb) and CARVYKTIT (Janssen Biotech / Legend Biotech). It is worth mentioning that, recently, KIMMTRAK (Immunocore) became the first T-cell receptor (TCR) therapy to receive approval from the USFDA.

Presently, more than 250 companies are engaged in the development of more than 1,200 early and late-stage T-cell therapies, worldwide. Several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace.

Over 6,800 patents related to CAR-T therapies, TCR therapies and TIL therapies have been recently filed / granted, demonstrating the continued innovation in this domain. In addition, close to 440 collaborations have been inked between industry / academic stakeholders to advance the development of various pipeline candidates.

Moreover, to fund product development initiatives in this domain, capital investments worth USD 30 billion have been made by various private and public sector investors in the last few years. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the T-cell immunotherapy market is anticipated to witness substantial growth in the mid to long-term.

Key Questions Answered

• What are the prevalent R&D trends related to T-cell immunotherapies (specifically CAR-Ts, TCRs and TILs)?
• What kind of clinical conditions can be treated using T-cell immunotherapies?
• Who are the leading industry and non-industry players in this market?
• In which geographies extensive research on T-cell immunotherapy is being conducted?
• What kind of partnership models are commonly adopted by industry stakeholders?
• Who are the key investors in T-cell immunotherapy domain?
• Who are the key opinion leaders / experts from renowned academic and research institutes who can help drive product development efforts in this domain?
• How is the intellectual property landscape for global T-cell therapies likely to evolve in the foreseen future?
• Who are the key service providers (CMOs / CDMOs) with capabilities to develop and manufacture T-cell therapies?
• What are the key factors that are likely to influence the evolution of the T-cell immunotherapies market?
• How is the current and future market opportunity likely to be distributed across key market segments?
• What are the key promotional strategies used by companies having marketed products?

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. CAR-T CELL THERAPIES: MARKET LANDSCAPE

5. TCR-BASED THERAPIES: MARKET LANDSCAPE

6. TIL-BASED THERAPIES: MARKET LANDSCAPE

7. KEY INSIGHTS

8. CLINICAL TRIAL ANALYSIS

9. KEY OPINION LEADERS

10. CAR-T CELL THERAPY PROFILES

11. TCR-BASED THERAPY PROFILES

12. TIL-BASED THERAPY PROFILES

13. EMERGING TECHNOLOGIES

14. PARTNERSHIPS AND COLLABORATIONS

15. FUNDING AND INVESTMENT ANALYSIS

16. PATENT ANALYSIS

17. OTHER T-CELL IMMUNOTHERAPIES

18. CASE STUDY: CELL THERAPY MANUFACTURING

19. COST PRICE ANALYSIS

20. MARKET FORECAST AND OPPORTUNITY ANALYSIS

21. PROMOTIONAL ANALYSIS

22. COMPANY PROFILES

23. CONCLUDING REMARKS

24. EXECUTIVE INSIGHTS

25. APPENDIX 1: TABULATED DATA

26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/1hio5z

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900